Association of a novel long non-coding RNA in 8q24 with prostate cancer susceptibility - PubMed (original) (raw)
. 2011 Jan;102(1):245-52.
doi: 10.1111/j.1349-7006.2010.01737.x. Epub 2010 Sep 28.
Hidewaki Nakagawa, Motohide Uemura, Lianhua Piao, Kyota Ashikawa, Naoya Hosono, Ryo Takata, Shusuke Akamatsu, Takahisa Kawaguchi, Takashi Morizono, Tatsuhiko Tsunoda, Yataro Daigo, Koichi Matsuda, Naoyuki Kamatani, Yusuke Nakamura, Michiaki Kubo
Affiliations
- PMID: 20874843
- DOI: 10.1111/j.1349-7006.2010.01737.x
Free article
Association of a novel long non-coding RNA in 8q24 with prostate cancer susceptibility
Suyoun Chung et al. Cancer Sci. 2011 Jan.
Free article
Abstract
Recent genome-wide association studies reported strong and reproducible associations of multiple genetic variants in a large "gene-desert" region of chromosome 8q24 with susceptibility to prostate cancer (PC). However, the causative or functional variants of these 8q24 loci and their biological mechanisms associated with PC susceptibility remain unclear and should be investigated. Here, focusing on its most centromeric region (so-called Region 2: Chr8: 128.14-128.28 Mb) among the multiple PC loci on 8q24, we performed fine mapping and re-sequencing of this critical region and identified SNPs (single nucleotide polymorphisms) between rs1456315 and rs7463708 (chr8: 128,173,119-128,173,237 bp) to be most significantly associated with PC susceptibility (P = 2.00 × 10(-24) , OR = 1.74, 95% confidence interval = 1.56-1.93). Importantly, we show that this region was transcribed as a ∼13 kb intron-less long non-coding RNA (ncRNA), termed PRNCR1 (prostate cancer non-coding RNA 1), and PRNCR1 expression was upregulated in some of the PC cells as well as precursor lesion prostatic intraepithelial neoplasia. Knockdown of PRNCR1 by siRNA attenuated the viability of PC cells and the transactivation activity of androgen receptor, which indicates that PRNCR1 could be involved in prostate carcinogenesis possibly through androgen receptor activity. These findings could provide a new insight in understanding the pathogenesis of genetic factors for PC susceptibility and prostate carcinogenesis.
© 2010 Japanese Cancer Association.
Similar articles
- Chromosome 8q24 risk variants in hereditary and non-hereditary prostate cancer patients.
Sun J, Lange EM, Isaacs SD, Liu W, Wiley KE, Lange L, Gronberg H, Duggan D, Carpten JD, Walsh PC, Xu J, Chang BL, Isaacs WB, Zheng SL. Sun J, et al. Prostate. 2008 Apr 1;68(5):489-97. doi: 10.1002/pros.20695. Prostate. 2008. PMID: 18213635 - IRX4 at 5p15 suppresses prostate cancer growth through the interaction with vitamin D receptor, conferring prostate cancer susceptibility.
Nguyen HH, Takata R, Akamatsu S, Shigemizu D, Tsunoda T, Furihata M, Takahashi A, Kubo M, Kamatani N, Ogawa O, Fujioka T, Nakamura Y, Nakagawa H. Nguyen HH, et al. Hum Mol Genet. 2012 May 1;21(9):2076-85. doi: 10.1093/hmg/dds025. Epub 2012 Feb 8. Hum Mol Genet. 2012. PMID: 22323358 - Association of chromosomal locus 8q24 and risk of prostate cancer: a hospital-based study of German patients treated with brachytherapy.
Meyer A, Schürmann P, Ghahremani M, Kocak E, Brinkhaus MJ, Bremer M, Karstens JH, Hagemann J, Machtens S, Dörk T. Meyer A, et al. Urol Oncol. 2009 Jul-Aug;27(4):373-6. doi: 10.1016/j.urolonc.2008.04.010. Epub 2008 Jul 14. Urol Oncol. 2009. PMID: 18625567 - Prostate cancer genomics by high-throughput technologies: genome-wide association study and sequencing analysis.
Nakagawa H. Nakagawa H. Endocr Relat Cancer. 2013 Jun 24;20(4):R171-81. doi: 10.1530/ERC-13-0113. Print 2013 Aug. Endocr Relat Cancer. 2013. PMID: 23625613 Review.
Cited by
- Non-coding RNAs as therapeutic targets in cancer and its clinical application.
Leng X, Zhang M, Xu Y, Wang J, Ding N, Yu Y, Sun S, Dai W, Xue X, Li N, Yang Y, Shi Z. Leng X, et al. J Pharm Anal. 2024 Jul;14(7):100947. doi: 10.1016/j.jpha.2024.02.001. Epub 2024 Feb 8. J Pharm Anal. 2024. PMID: 39149142 Free PMC article. Review. - Comparative RNA Genomics.
Backofen R, Gorodkin J, Hofacker IL, Stadler PF. Backofen R, et al. Methods Mol Biol. 2024;2802:347-393. doi: 10.1007/978-1-0716-3838-5_12. Methods Mol Biol. 2024. PMID: 38819565 - Pro-tumorigenic role of lnc-ZNF30-3 as a sponge counteracting miR-145-5p in prostate cancer.
Le Hars M, Castro-Vega LJ, Rajabi F, Tabatadze D, Romero M, Pinskaya M, Groisman I. Le Hars M, et al. Biol Direct. 2023 Jul 11;18(1):38. doi: 10.1186/s13062-023-00393-7. Biol Direct. 2023. PMID: 37434219 Free PMC article. - Identification of long noncoding RNAs with aberrant expression in prostate cancer metastases.
Sattari M, Kohvakka A, Moradi E, Rauhala H, Urhonen H, Isaacs WB, Nykter M, Murtola TJ, Tammela TLJ, Latonen L, Bova GS, Kesseli J, Visakorpi T. Sattari M, et al. Endocr Relat Cancer. 2023 Jun 26;30(8):e220247. doi: 10.1530/ERC-22-0247. Print 2023 Aug 1. Endocr Relat Cancer. 2023. PMID: 37140987 Free PMC article. - Prostate Cancer Epigenetic Plasticity and Enhancer Heterogeneity: Molecular Causes, Consequences and Clinical Implications.
Kneppers J, Bergman AM, Zwart W. Kneppers J, et al. Adv Exp Med Biol. 2022;1390:255-275. doi: 10.1007/978-3-031-11836-4_15. Adv Exp Med Biol. 2022. PMID: 36107324 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous